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BACKGROUND: Gestational trophoblastic neoplasia (GTN) after a hydatidiform mole is either treated with single- or multi-agent
chemotherapy determined by a multifactorial scoring system. Women with human chorionic gonadotrophin (hCG) levels
4100000IUl
 1 can remain within the low-risk/single-agent category and usually choose one drug therapy. Here we compare the
success and duration of single- vs multi-agent chemotherapy in this patient group.
METHODS: Between 1980 and 2008, 65 women had a pre-treatment hCG 4100000IUl
 1 and were low risk. The initial hCG level,
treatment regimens, changes and duration and overall survival were recorded.
RESULTS: Of 37 patients starting low-risk/single-agent treatment, 11 (29.7%) were treated successfully, whereas 26 (70.3%) required
additional multi-agent chemotherapy to achieve complete remission (CR). Combination chemotherapy was initially commenced in 28
women, and 2 (7%) required additional drugs for CR. The overall duration of therapy for those commencing and completing single-
or multi-agent chemotherapy was 130 and 123 days (P¼0.78), respectively. The median-treatment duration for patients
commencing single-agent but changing to multi-agent chemotherapy was 13 days more than those receiving high-risk treatment alone
(136 vs 123 days; P¼0.07). All 3 patients with an initial hCG 4400000IUl
 1 and treated with single-agent therapy developed drug
resistance. Overall survival for all patients was 100%.
CONCLUSION: Low-risk post-molar GTN patients with a pre-treatment hCG 4100000 and o400000IUl
 1 can be offered low-risk
single-agent therapy, as this will cure 30%, is relatively non-toxic and only prolongs treatment by 2 weeks if a change to combination
agents is required. Patients whose hCG is 4400000IUl
 1 should receive multi-agent chemotherapy from the outset.
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Gestational trophoblastic disease (GTD) is a spectrum of
pregnancy-related disorders the commonest of which are the
pre-malignant complete (CM) and partial (PM) hydatidiform mole
(Sebire and Seckl, 2008). In the United Kingdom, CM and PM
affects 1 and 3 per 1000 pregnancies, respectively. They usually
present with vaginal bleeding in the first trimester or with
abnormal routine ultrasonography at 10–12 weeks gestation
(reviewed in Sebire and Seckl, 2008). Initial treatment involves
uterine evacuation, which also enables a histopathological
diagnosis. In the vast majority of cases, any residual disease
resolves spontaneously over time but in 16% of CM and 0.5% of
PM, persisting disease can develop (Seckl et al, 2000). Fortunately,
GTD including CM and PM all produce the pregnancy hormone
human chorionic gonadotrophin (hCG). In women where residual
CM or PM is dying out, the hCG concentration in serum and/or
urine falls. However, a plateaued or rising hCG is an early sign of
persisting disease which usually requires chemotherapy, so hCG
follow-up is crucial.
In the United Kingdom, all women with GTD are registered for
hCG follow-up with one of three centres located in Dundee,
Sheffield and London and treated in either of the latter two.
Women with persisting disease are only considered for repeat
uterine evacuation in the UK when the hCG is o5000IUl
 1 and
ultrasound imaging suggests that the disease is confined to the
uterine cavity. Analysis in our centre has shown that once the hCG
exceeds 5000IUl
 1, 70% of patients, despite a second evacuation,
will require chemotherapy usually in the form of single-agent
methotrexate and folinic acid (MTX–FA) (Savage and Seckl, 2005).
This has relatively few side effects and is curative in most, whereas
a further evacuation carries a small risk of uterine perforation,
especially if endometrial invasion is present. Moreover, if the hCG
exceeds 100000IUl
 1 and the uterine mass is large, the potential
benefit of a second evacuation is very small and the risks of
haemorrhage and perforation increase. Similar findings have been
reported by others (Pezeshki et al, 2004).
Although MTX–FA will help most patients with gestational
trophoblastic neoplasia (GTN) following a molar pregnancy, some
will require combination chemotherapy most commonly with
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setoposide, methotrexate and actinomycin D alternating weekly
with cyclophosphamide and vincristine (EMA–CO), which is now
widely used around the world (Bolis et al, 1988; Bagshawe et al,
1989; Newlands et al, 1991; Kim et al, 2004; Turan et al, 2006). So
how are patients selected for single-agent MTX–FA vs multi-agent
EMA–CO chemotherapy?
Several factors are important predictors of disease that will
become resistant to single-agent chemotherapy, including the size,
number and location of metastases, time from the antecedent
pregnancy event to treatment, type of antecedent pregnancy,
patient age and hCG level (Bagshawe, 1976). These factors form
the basis of the International Federation of Gynecology and
Obstetrics (FIGO) scoring system, which correlates with the risk
of developing disease resistant to single-agent therapy (Kohorn
et al, 2000). Although the scoring system has been very helpful
there are still some areas where it is possible that the information
derived for determining the type of therapy could be refined. One
such area relates to the level of hCG before chemotherapy.
The scoring for hCG concentrations are 0 for o1000IUl
 1,1
for 1000–10000IUl
 1, 2 for 10000–100000IUl
 1 and 4 for
4100000IUl
 1. A total score of 0–6 classifies patients as low-risk,
whereas a score 46 identifies patients as high-risk and selects
them for multi-agent chemotherapy. Most patients with an hCG of
over 100000IUl
 1 score additional points for tumour volume and
metastases placing them as 46 but a few women score 6 or less
and are therefore technically low-risk. Such patients may have hCG
levels that are much higher (e.g., over 500000IUl
 1) and might
be expected to have a very small chance of being cured with
single-agent therapy.
At our institute, patients with an hCG of 4100000IUl
 1 and a
FIGO score of p6 have been involved in the decision of whether to
treat with MTX–FA or EMA–CO. MTX–FA has little short-term
toxicity and no appreciable long-term toxicity (McNeish et al,
2002). In contrast, EMA–CO causes alopecia and myelosuppres-
sion, brings forward the menopause by 3 years and increases the
risk of second malignancies by approximately 1.5 fold (Rustin
et al, 1996; Bower et al, 1998). As a result, many patients select
MTX–FA treatment, whereas some choose EMA–CO in the belief
that it is more likely to cure them rapidly.
In this study, we have retrospectively compared the outcomes
for women with low-risk GTN and a pre-treatment hCG value
4100000IUl
 1, treated with either MTX–FA or EMA–CO as
their initial therapy. We specifically examine the risk of drug
resistance in those commencing single-agent MTX–FA and the
total duration of therapy required to induce a sustained remission.
We also ask whether there is an hCG level beyond which there is
no point in trying MTX–FA therapy in low-risk patients.
MATERIALS AND METHODS
Between January 1980 and May 2008, 2050 women with post-
hydatidiform mole GTN were treated at Charing Cross Hospital. Of
these, 174 had an admission hCG value of over 100000IUl
 1. All
patients underwent radiological investigation with a Doppler and
ultrasound scan of the pelvis and chest X-ray to assess the
maximum diameter of the uterine mass and the presence of lung
metastases. Patients were stratified according to the Charing Cross
system (Bagshawe, 1976) and after 2000, also the FIGO scoring
system (Table 1) (Kohorn et al, 2000). To simplify the analysis and
render it relevant to current practise, all patients scored with the
Charing Cross system before 2000 had this value converted to the
new FIGO system. Scores totalling 0–6 were classified as low-risk,
and those scoring 7 or above were classified as high-risk. Only
those patients scoring low-risk were selected for further analysis in
this report. These patients were informed of the benefits, toxicity
profiles and likelihood of cure for both the low-risk treatment with
8-day MTX–FA (intramuscular MTX 50mg days 1,3,5 and 7 and
oral FA 15mg days 2, 4, 6 and 8) and high-risk treatment with
EMA–CO (intravenous etoposide 100mgm
 2 days 1 and 2, MTX
300mgm
 2 day 1, actinomycin D 0.5mg days 1 and 2, cyclophos-
phamide 600mgm
 2 and vincristine 0.8mgm
 2 day 8) as
previously described (McNeish et al, 2002), and were encouraged
to participate in the treatment decision process. Serum hCG values
were measured twice weekly during treatment and in the presence
of three static or two rising hCG values, patients were defined as
having drug-resistant disease.
In the case of low-risk patients developing resistance to
MTX–FA, treatment was escalated to actinomycin D (0.5mgs
intravenously days 1–5 every 2 weeks) if the hCG level was
o100IUl
 1 at the point of resistance, or to the EMA–CO regime if
the hCG was 4100IUl
 1 as previously described (McNeish et al,
2002). If patients developed side effects from MTX, the FA dose
was initially increased, however, if symptoms persisted they were
also converted to an alternative regimen as previously described
(McNeish et al, 2002). For patients developing resistance to EMA–
CO, then we have previously added cisplatin by combining with
etoposide and alternating weekly with EMA, in which the second
day of the EMA is omitted (Newlands et al, 2000). More recently,
we have developed a less toxic alternative comprising paclitaxel
and etoposide alternating two weekly with paclitaxel and cisplatin
(TE–TP) (Wang et al, 2008).
Treatment was continued for 6–8 weeks after the normalisation
of the serum hCG (i.e. o5IUl
 1) after which, lifelong hCG
monitoring commenced. Relapsed disease was characterised as a
rise in serum hCG value Z6 weeks after normalisation, in the
absence of a new pregnancy.
The INSTAT Statistics program was used for the analysis of data
using median hCG values and median duration of treatment, and
application of the Mann–Whitney test for comparison of these
variables.
This retrospective analysis was accepted by our local Institu-
tional Review Board.
RESULTS
Between January 1980 and May 2008, 65 (37%) of the 174 patients
with hCG values 4100000IUl
 1 had a FIGO Score of 6 or below
(Figure 1). In all, 37 (56.9%) of these 65 patients were commenced
on low-risk MTX–FA therapy, with 18 of those scoring 6, 18
scoring 5 and only 1 patient scoring 4, reflecting the fact that an
hCG 4100000 warrants 4 points alone. Of the 37 patients
commencing MTX–FA, 11 (29.7%) with an initial median hCG
reading of 142473IUl
 1 (range 101510–322461) were cured
without requiring a change of therapy (Figure 1 and Table 2).
However, 26 patients (70.3%) with an initial median hCG of
136287IUl
 1 (range 102199–1217592) required a change to
EMA–CO. There was no significant difference between these hCG
median values (P¼0.58) as shown in Table 3. The highest hCG
value successfully treated by MTX–FA alone was 322461IUl
 1.
Three patients had hCG values exceeding this (414876, 423563 and
1217592), and all required a change to EMA–CO.
All patients who changed from MTX–FA therapy had an hCG
4100IUl
 1 and so none received actinomycin D (McNeish et al,
2002). EMA–CO was given in 26 such patients, 24 because of
MTX–FA resistance, 1 because of toxicity and 1 patient relapsed
within 6 weeks of completing MTX–FA therapy. In one individual,
a further change in treatment from EMA–CO to etoposide and
cisplatin alternating weekly with etoposide, methotrexate and
actinomycin D (EP–EMA) was made because of an hCG plateau;
however, there have not been any other documented relapses in
these patients. The overall survival rate for the 65 patients with
low-risk scores and hCG 4100000IUl
 1 was 100%.
In total, 28 (43.1%) of the 65 patients were commenced on high-
risk EMA–CO treatment in the first instance, with 19 having a
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sFIGO score of 6 and 9 with a score of 5. Only two patients required
additional chemotherapy to effect a sustained remission (Figure 1).
The initial median hCG reading for this group was 239903IUl
 1
(range 102732–1843371). This was significantly higher than
the median hCG of those patients commencing and either
completing MTX–FA (P¼0.01) or changing to EMA–CO
(P¼0.002) (Tables 2 and 3).
Comparing those patients that completed MTX–FA, with those
who received EMA–CO straight away, there was no significant
difference in the total length of treatment (P¼0.78). The median
duration of treatment with MTX–FA alone was 130 days (range
78–180), and the median duration of treatment for EMA–CO was
123 days (range 74–247). There was no significant difference in
the median duration of treatment between those patients that
Table 1 FIGO scoring system for gestational trophoblastic disease
FIGO scoring system
Variable 0 1 2 4
Age (years) o40 X40 — —
Antecedent pregnancy (AP) Mole Abortion or unknown Term —
Interval, that is end of AP to start of treatment (months) o44 – 7 7 – 1 2 412
Human chorionic gonadotrophin (hCG) (IUl
 1) o1000 1000–10000 10000–100000 4100000
Largest mass (cm) o33 – 5 45—
Site of metastases Nil or lungs Spleen, kidney GI tract Brain, liver
No. of metastases 0 1–4 5–8 48
Previous chemotherapy — — Single agent 41 drug
Type to enter text
Cure
hCG > 100 000 IU l–1
(N=174)
FIGO score6 
37.4%
(N=65)
EMA–CO
43.1%
(N=28)
MTX–FA
56.9%
(N=37)
Completed MTX–FA
29.7%
(N=11)
Change to EMA–CO
70.3%
(N=26)
Change to EP–EMA
7.1%
(N=2)
Change to EP–EMA
3.8%
(N=1)
Figure 1 Flow diagram depicting outcomes of patients presenting with human chorionic gonadotrophin (hCG) 4100000IUl
 1.
Table 2 Data comparisons between the three treatment groups in patients presenting with human chorionic gonadotrophin (hCG) 4100000IUl
 1 and
FIGO score p6
MTX–FA MTX–FA+EMA–CO EMA–CO
Number of patients 11 26 28
Median initial hCG (IUl
 1) 142473 136287 239903
Range 101510–322461 102199–1217592 102732–1843371
Median duration of treatment (days) 130 136 123
Range 78–180 102–181 74–247
Abbreviations: CO¼cyclophosphamideþvincristine; EMA¼etoposideþmethotrexateþactinomycin D; FA¼folinic acid; MTX¼methotrexate.
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EMA–CO that is, 130 days compared with 136 days (P¼0.07).
However, there was a non-significant 13 day increase (P¼0.07) in
treatment duration in those patients commencing MTX–FA but
ultimately requiring a change in treatment, compared with those
commencing EMA–CO in the first instance (Tables 2 and 3).
DISCUSSION
Gestational trophoblastic neoplasia is highly responsive to chemo-
therapy and prognosis is excellent following treatment, especially in
low-risk patients (Ngan and Seckl, 2007). In selecting the most
appropriate therapy, it is important to minimise toxicity, both in
terms of short- and long-term side effects while preserving efficacy.
Several previous studies have examined the link between hCG
levels and the likelihood of resistance to MTX. Berkowitz et al
(1982) noted that resistance to MTX–FA was more common with
pre-treatment hCG titres greater than or equal to 50000IUl
 1 but
some patients could still be cured. The experience of Bolis et al
(1987) suggested that drug resistance and relapse rate was related to
an hCG value higher than 10000IUl
 1 when using MTX–FA,
whereas Gleeson et al (1993) demonstrated that 50% of those with a
pre-treatment hCG of greater than 650IUl
 1,f a i l e dp r i m a r yw e e k l y
MTX therapy. Chen et al (2004) concluded that single-agent pulse
actinomycin D had only modest activity for methotrexate-resistant
GTN, with hCG levels being lower in responders (mean 37 vs 3634).
They postulated that prediction of remission may be more closely
associated with hCG levels than with FIGO score alone. However,
none of these studies have addressed the outcome for patients with
an hCG 4100000 IUl
 1 who still score in the low-risk category.
The EMA/CO regimen is associated with greater toxicity than
low-risk single-agent treatment, including alopecia, myelosuppres-
sion, a reduction in the age of menopause and the increased risk of
a second malignancy (Rustin et al, 1996; Bower et al, 1998). As
low-risk MTX–FA conveys less toxicity, should patients with low-
risk FIGO scores but with high hCG values at least be offered this
treatment initially? If resistance does develop, warranting a change
in treatment, is the total treatment duration significantly increased,
and does there appear to be any difference in the outcome?
In this cohort of 65 patients with hCG values of over
100000IUl
 1 and with low-risk FIGO scores, 37 (56.9%) were
commenced on low-risk MTX–FA treatment, the remainder
commencing high-risk EMA–CO treatment. Of those patients in
the former group, there was a 70.3% chance of having to change to
high-risk treatment, and this was mostly as a result of MTX–FA
resistance. This compares with 33.2% risk in the McNeish study
(McNeish et al, 2002), which mainly included lower admission
hCG values and therefore lower FIGO score patients. Despite the
high rate of treatment resistance, we believe that MTX–FA
treatment in low-risk patients is still a viable treatment option as
a number of women will be spared the extra toxicity of multi-drug
etoposide-based therapy. Many patients are happy to commence
initial low-risk therapy, if there is a chance that they can avoid
toxicity, as long as it does not compromise their overall outcome.
There was no significant difference in the median hCG values
when comparing the group that completed low-risk treatment with
those that required a change of treatment. However, once the hCG
rose above 400000IUl
 1, which occurred in three patients, all
developed MTX–FA resistance. Clearly patient numbers are
limited, but these data suggest that if the presentation hCG values
exceed 400000IUl
 1, such individuals might best be treated with
multi-agent chemotherapy in the first instance, regardless of a low-
risk FIGO score. We do not believe that any other study has
previously examined the question of whether there is an hCG level
beyond which therapy with single-agent MTX–FA may be
completely futile in women who still score as low risk.
The remaining 43.1% of patients were commenced on high-risk
EMA–CO treatment straight away. It is interesting to note that
there was no significant difference in the total duration of
treatment when comparing this group with those that completed
MTX–FA (123 vs 130 days). Hence, it is possible to offer patients
the choice between treatments, ensuring that they are fully aware
of the side-effect profiles for both regimens and the 70.3% chance
of developing MTX–FA resistance. Nevertheless, if they do
commence MTX–FA and develop resistance or toxicity warranting
a regimen change, there is a non-significant increase in the total
duration of treatment. Indeed, if a regimen change is required,
length of treatment is likely to increase by just 13 days compared
with EMA–CO alone, or by 6 days compared with MTX–FA alone.
As the entire treatment duration can vary from 74 to 247 days, a
potential increase of 13 days by commencing MTX–FA rather than
EMA–CO is probably not of great concern to patients particularly
when this is balanced against the toxicity profiles of the two
regimens.
There is increasing interest in using pulsed or 5-day actinomycin
D rather than MTX–FA as the initial therapy for low-risk treatment,
as this single-agent alternative may produce a slightly improved
chance of inducing remission (Gilani et al, 2005; Osborne et al, 2008;
Yarandi et al, 2008). It is also thought that actinomycin D may result
in a shorter duration of treatment. However, our results suggest that
the latter treatment is unlikely to produce significantly faster cures,
as the much more potent EMA–CO regimen only reduced treatment
duration by an average of 1 week compared with MTX–FA. As in
our experience, actinomycin D is more toxic than MTX–FA
(McNeish et al, 2002), we continue to use the latter as initial
therapy for low-risk patients.
Reassuringly, there did not appear to be any difference in the
outcome between those completing MTX–FA, requiring a regimen
change and commencing combination chemotherapy, in terms of
overall survival. This study had a 100% overall survival rate;
however, as some patients completed treatment as recently as
August 2008, we did not have long-term survival data available on
all patients.
In summary, our data suggests that it is reasonable to commence
the less-toxic MTX–FA therapy in women presenting with low-risk
post-molar GTN and an hCG 4100000 and o400000IUl
 1.
Moreover, treating patients until methotrexate resistance is evident
and then changing to multi-agent chemotherapy, only prolongs
treatment by an average of 2 weeks, and does not compromise the
long-term survival of patients. However, in those with an hCG
4400000IUl
 1, MTX–FA does not appear to work and these
individuals will likely do better by commencing therapy with
EMA–CO.
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Table 3 Statistical comparisons between the three treatment groups in
patients presenting with human chorionic gonadotrophin (hCG)
4100000IUl
 1 and FIGO score p6( P-values obtained using the
Mann–Whitney test)
Regime
Median initial
hCG (IUl
 1)
Median duration of
treatment (days)
MTX–FA vs MTX–FA+EMA–CO P¼0.58 P¼0.07
MTX–FA vs EMA–CO P¼0.01 P¼0.78
MTX–FA+EMA–CO vs EMA–CO P¼0.002 P¼0.07
Abbreviations: CO¼cyclophosphamideþvincristine; EMA¼etoposideþmetho-
trexateþactinomycin D; FA¼folinic acid; MTX¼methotrexate.
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